SIGA Technologies (NASDAQ:SIGA) secures $113M TPOXX order
Full story: https://grafa.com/news/siga-technologies--nasdaq-siga--secures--113m-tpoxx-order-249146
SIGA Technologies (NASDAQ:SIGA), a leader in pharmaceutical innovation, today announced a significant development in its partnership with the U.S. Department of Health and Human Services.
The Department has exercised a procurement option under the existing contract (number 75A50118C00019), ordering approximately $113 million worth of oral TPOXX® courses.
This order is part of ongoing efforts to enhance the United States' preparedness against orthopoxviruses, which include smallpox and mpox (monkeypox), among others.
Diem Nguyen, the CEO of SIGA, highlighted the importance of this order, stating, "Following multiple orders in 2023 from the U.S. government and 15 international clients, this substantial investment by the U.S. will bolster our readiness and response capabilities for public health emergencies stemming from natural, accidental, or intentional threats."
Nguyen also expressed satisfaction with the company's role in reinforcing global health security while ensuring profitable returns for its stakeholders.
This funding from the U.S. government, facilitated through the Administration for Strategic Preparedness and Response and the Biomedical Advanced Research and Development Authority (BARDA), underscores the critical nature of TPOXX®.
The drug is the first of its kind approved in the U.S. and Canada specifically for treating smallpox and is also authorized in Europe and the UK for treating various poxvirus-related conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
